Gallop Oncology is a clinical-stage biopharma company leading development of drugs targeting galectin-9, a pivotal oncogenic and immunosuppressive regulator of cancer processes
We are focused on transforming treatment paradigms for both hematologic and solid tumor indications. Our lead asset, LYT-200, has received Fast Track and Orphan Drug Designations for the treatment of acute myeloid leukemia (AML) and head and neck squamous cell carcinoma (HNSCC). With its dual mechanism of action—direct tumor suppression and immune modulation—LYT-200 represents a novel, differentiated approach in oncology therapeutics.
🎙️ New episode of The BioHub - Luba Greenwood, J.D. - Gallop Oncology!
Luba is one of the most thoughtful and honest voices in biotech and this conversation really shows that.
We talk about:
🔥 The realities of capital allocation in biotech
🔥 What boards and founders often get wrong
🔥 How to build companies that actually endure
It’s a candid, insightful discussion with someone who’s seen this industry from every angle.
🎧 Live now on YouTube, Spotify & Apple.
👉 Link in the comments.
#TheBioHub#Biotech#Leadership#Oncology
Proud to share our topline results from Phase 1b study at #ASH25 as we advance toward a potentially registrational Phase 2 study. This data mark a meaningful step forward for patients with relapsed/refractory AML and high-risk MDS, where therapeutic options remain extremely limited.
The initial Phase 1b data for LYT-200 demonstrate durable responses, a favorable safety profile, and overall survival outcomes that far exceed what is typically expected at this stage of disease. These findings provide what we believe is the first clinical validation of galectin-9 as a key therapeutic target—reinforcing its central role in AML biology and the broad potential of LYT-200 across high-risk patient subsets.
I am deeply grateful to the patients, families, investigators, and our entire team whose partnership made this progress possible.
#aml#MDS#oncolog#hematology#biotech#pharma#clinicaltrial#precisionmedicine#innovation#cure
We’re pleased to share compelling initial topline results from our Phase 1b trial of LYT-200 in relapsed/refractory #AML and high-risk #MDS.
Our CEO, Luba Greenwood, J.D., said "Patients with relapsed/refractory AML or high-risk MDS face extremely limited treatment options, and overall survival at this stage is typically less than 2.5 months. With LYT-200, we have demonstrated durable responses, enabled a substantially meaningful proportion of patients to proceed to transplant, and shown initial median overall survival data of 13.2 months at the proposed Phase 2 dose - all alongside a very favorable safety profile. Together, these findings represent a potential step change in the treatment of AML. Importantly, these compelling results were observed in patients across several high-risk mutations, underscoring the central role of galectin-9 in driving this disease as well as the potential broad applicability of LYT-200 in AML and beyond. The strength of the data gives us confidence as we advance toward a potentially registrational Phase 2 study in AML and supports future evaluation of LYT-200 in earlier lines of treatment. We look forward to engaging with regulatory authorities once the maturing overall survival data are finalized."
These results show the power of targeting galectin-9 and mark an important step as we move toward the next phase of development. To our knowledge, these data are the first clinical validation of galectin-9 as a key therapeutic target and underscore strong biological activity, a favorable safety profile, and clinical benefit.
We look forward to presenting more tomorrow at #ASH25, and we extend our sincerest gratitude to the patients, families, and investigators whose partnership have made this progress possible. https://bit.ly/3XzOjU7
Proud to share our topline results from Phase 1b study at #ASH25 as we advance toward a potentially registrational Phase 2 study. This data mark a meaningful step forward for patients with relapsed/refractory AML and high-risk MDS, where therapeutic options remain extremely limited.
The initial Phase 1b data for LYT-200 demonstrate durable responses, a favorable safety profile, and overall survival outcomes that far exceed what is typically expected at this stage of disease. These findings provide what we believe is the first clinical validation of galectin-9 as a key therapeutic target—reinforcing its central role in AML biology and the broad potential of LYT-200 across high-risk patient subsets.
I am deeply grateful to the patients, families, investigators, and our entire team whose partnership made this progress possible.
#aml#MDS#oncolog#hematology#biotech#pharma#clinicaltrial#precisionmedicine#innovation#cure
We’re pleased to share compelling initial topline results from our Phase 1b trial of LYT-200 in relapsed/refractory #AML and high-risk #MDS.
Our CEO, Luba Greenwood, J.D., said "Patients with relapsed/refractory AML or high-risk MDS face extremely limited treatment options, and overall survival at this stage is typically less than 2.5 months. With LYT-200, we have demonstrated durable responses, enabled a substantially meaningful proportion of patients to proceed to transplant, and shown initial median overall survival data of 13.2 months at the proposed Phase 2 dose - all alongside a very favorable safety profile. Together, these findings represent a potential step change in the treatment of AML. Importantly, these compelling results were observed in patients across several high-risk mutations, underscoring the central role of galectin-9 in driving this disease as well as the potential broad applicability of LYT-200 in AML and beyond. The strength of the data gives us confidence as we advance toward a potentially registrational Phase 2 study in AML and supports future evaluation of LYT-200 in earlier lines of treatment. We look forward to engaging with regulatory authorities once the maturing overall survival data are finalized."
These results show the power of targeting galectin-9 and mark an important step as we move toward the next phase of development. To our knowledge, these data are the first clinical validation of galectin-9 as a key therapeutic target and underscore strong biological activity, a favorable safety profile, and clinical benefit.
We look forward to presenting more tomorrow at #ASH25, and we extend our sincerest gratitude to the patients, families, and investigators whose partnership have made this progress possible. https://bit.ly/3XzOjU7
Proud to share our topline results from Phase 1b study at #ASH25 as we advance toward a potentially registrational Phase 2 study. This data mark a meaningful step forward for patients with relapsed/refractory AML and high-risk MDS, where therapeutic options remain extremely limited.
The initial Phase 1b data for LYT-200 demonstrate durable responses, a favorable safety profile, and overall survival outcomes that far exceed what is typically expected at this stage of disease. These findings provide what we believe is the first clinical validation of galectin-9 as a key therapeutic target—reinforcing its central role in AML biology and the broad potential of LYT-200 across high-risk patient subsets.
I am deeply grateful to the patients, families, investigators, and our entire team whose partnership made this progress possible.
#aml#MDS#oncolog#hematology#biotech#pharma#clinicaltrial#precisionmedicine#innovation#cure
We’re pleased to share compelling initial topline results from our Phase 1b trial of LYT-200 in relapsed/refractory #AML and high-risk #MDS.
Our CEO, Luba Greenwood, J.D., said "Patients with relapsed/refractory AML or high-risk MDS face extremely limited treatment options, and overall survival at this stage is typically less than 2.5 months. With LYT-200, we have demonstrated durable responses, enabled a substantially meaningful proportion of patients to proceed to transplant, and shown initial median overall survival data of 13.2 months at the proposed Phase 2 dose - all alongside a very favorable safety profile. Together, these findings represent a potential step change in the treatment of AML. Importantly, these compelling results were observed in patients across several high-risk mutations, underscoring the central role of galectin-9 in driving this disease as well as the potential broad applicability of LYT-200 in AML and beyond. The strength of the data gives us confidence as we advance toward a potentially registrational Phase 2 study in AML and supports future evaluation of LYT-200 in earlier lines of treatment. We look forward to engaging with regulatory authorities once the maturing overall survival data are finalized."
These results show the power of targeting galectin-9 and mark an important step as we move toward the next phase of development. To our knowledge, these data are the first clinical validation of galectin-9 as a key therapeutic target and underscore strong biological activity, a favorable safety profile, and clinical benefit.
We look forward to presenting more tomorrow at #ASH25, and we extend our sincerest gratitude to the patients, families, and investigators whose partnership have made this progress possible. https://bit.ly/3XzOjU7
We’re pleased to share compelling initial topline results from our Phase 1b trial of LYT-200 in relapsed/refractory #AML and high-risk #MDS.
Our CEO, Luba Greenwood, J.D., said "Patients with relapsed/refractory AML or high-risk MDS face extremely limited treatment options, and overall survival at this stage is typically less than 2.5 months. With LYT-200, we have demonstrated durable responses, enabled a substantially meaningful proportion of patients to proceed to transplant, and shown initial median overall survival data of 13.2 months at the proposed Phase 2 dose - all alongside a very favorable safety profile. Together, these findings represent a potential step change in the treatment of AML. Importantly, these compelling results were observed in patients across several high-risk mutations, underscoring the central role of galectin-9 in driving this disease as well as the potential broad applicability of LYT-200 in AML and beyond. The strength of the data gives us confidence as we advance toward a potentially registrational Phase 2 study in AML and supports future evaluation of LYT-200 in earlier lines of treatment. We look forward to engaging with regulatory authorities once the maturing overall survival data are finalized."
These results show the power of targeting galectin-9 and mark an important step as we move toward the next phase of development. To our knowledge, these data are the first clinical validation of galectin-9 as a key therapeutic target and underscore strong biological activity, a favorable safety profile, and clinical benefit.
We look forward to presenting more tomorrow at #ASH25, and we extend our sincerest gratitude to the patients, families, and investigators whose partnership have made this progress possible. https://bit.ly/3XzOjU7
Really energised after the EY & Goodwin Healthcare Symposium yesterday, co-hosted during the Jefferies Healthcare Conference.
It was a privilege to moderate the session on Next wave of Healthcare M&A with a distinguished panel including – Maarten de Jong , Luba Greenwood, J.D., Marton Kenessey, Dr. Olga Kubassova and William Deacon.
The insights and personal examples shared across the panels highlight just how fast the sector is evolving and where the next curve of growth is emerging.
A few standout themes shaping the conversation:
✅ Capital efficiency and disciplined scaling models are now essential - especially for pre-commercial biotech
✅ Alternative M&A approaches are gaining traction as dealmakers navigate a shifting market
✅ AI and data-driven technologies are transforming how we assess value, accelerate trials and make strategic decisions
✅ Investors are increasingly focused on platforms with clear pathways to impact and commercial sustainability
Great to see such a strong mix of operators, innovators, entrepreneurs and investors all bringing complementary perspectives to the table.
#EY#ShapingTheFutureWithConfidence#Healthcare#LifeSciences#HealthcareInnovation#HealthcareM&A #AIinHealthcare#HealthTech#JefferiesHealthcareConference#GoodwinLeo GribbenSuresh ChandraJonathan Lloyd-HirstSylvester OppongNegin NiroomandLaura Letts
💡 Biotech’s weathered storms before, this one’s testing our next-gen grit. How We Navigate It Defines Us.
I remember a partner once saying, “Markets don’t paralyze biotech. Muffled leadership does.”
That line has stayed with me especially in moments when the market tightens and the path forward feels uncertain.
The latest piece on BiotechTV nailed it: survival isn’t about predicting the next turn - it’s about staying in motion when the path blurs!
🧭 When clarity fades, alignment becomes your north star.
💬 When pressure mounts, storytelling keeps people believing.
🤝 When resources tighten, collaboration creates lift.
The latest “Optimistic Realism” discussion on @BiotechTV with, MassBio CEO Kendalle Burlin O'Connell, Esq. Normunity CEO Rachel W. Humphrey, MD and Gallop Oncology CEO Luba Greenwood, J.D., captures that spirit perfectly, a reminder that resilience and realism can coexist beautifully. It’s about leading with honesty, signaling that “it’s going to be okay,” and creating a space where people can lean into change with confidence.
If you’re leading in R&D, alliance management, or operational transformation, ask yourself:
→ How grounded is your team in why you’re here and what happens when the unexpected hits?
→ When the environment shifts, how quickly and visibly, can your culture realign?
Let's remember: Uncertain times don’t break biotech. They reveal its best leaders!
#Biotech#Leadership#Resilience#AllianceManagement#Collaboration#StrategicClarityhttps://lnkd.in/ewGUDHs3
We’re pleased to share that new data from our Phase 1b trial of LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, have been selected for presentation at the 67th American Society of Hematology Annual Meeting in December. #ASH25
"The combination of this level of efficacy with a clean safety profile underscores the importance of advancing LYT-200 into its next phase of development, especially given the high relapse rates and poor survival outcomes in AML," said Luba Greenwood, J.D., Chief Executive Officer of Gallop Oncology.
The accepted abstract reflects data as of July 8, 2025, showing strong evidence of clinical activity and a highly favorable safety profile in heavily pretreated patients with relapsed/refractory AML, both as monotherapy and in combination with standard-of-care therapy.
Additional analyses from a later data cut will be shared during #ASH, with topline efficacy and survival results anticipated in Q4 2025 and 1H 2026, respectively.
https://lnkd.in/eupt8ivE
We’re pleased to share that new data from our Phase 1b trial of LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, have been selected for presentation at the 67th American Society of Hematology Annual Meeting in December. #ASH25
"The combination of this level of efficacy with a clean safety profile underscores the importance of advancing LYT-200 into its next phase of development, especially given the high relapse rates and poor survival outcomes in AML," said Luba Greenwood, J.D., Chief Executive Officer of Gallop Oncology.
The accepted abstract reflects data as of July 8, 2025, showing strong evidence of clinical activity and a highly favorable safety profile in heavily pretreated patients with relapsed/refractory AML, both as monotherapy and in combination with standard-of-care therapy.
Additional analyses from a later data cut will be shared during #ASH, with topline efficacy and survival results anticipated in Q4 2025 and 1H 2026, respectively.
https://lnkd.in/eupt8ivE
It was a distinct privilege and honor to be invited as a panelist for the discussion titled 'The Future of Clinical Data in Business Development, Strategy, and Innovation' at the 3rd Agentic AI Innovation Summit!
#TheAgenticAIinnovationSummit#3rdAgenticAi#nference
While Agentic AI has been widely recognized and utilized as a strategic enabler for business development and innovation, it possesses the remarkable ability to integrate multimodal data, thereby enhancing clinical decision-making support.
In the process of embracing and deploying Agentic AI within healthcare and pharmaceutical drug development, it is crucial to strike a balance between the extensive capabilities of Agentic AI and the imperative of refining reasoning by holistically considering pathophysiology and human genetics.
This approach necessitates the adoption of tiered strategies that underscore the critical importance of data validity for concrete scenario projections and forecasting.
I would like to extend my sincere gratitude to Bruce Johnson for expertly chairing the vigorous and insightful panel discussion!
It was truly a great pleasure to engage in discussion with all the panelists!
Luba Greenwood, J.D.Chinmaya RathRupinder HargunStephen Mitchener
A HUGE THANK YOU to Venky Soundararajan, Ph.D. and Brian Urban!
A Special THANK YOUT for all the support! EMD Serono, Inc.Merck HealthcareMerck GroupAlice McGrail Clayton#AgenticAI#AI#AIinHealthCare#HealthcareAI#Reasoning#HumanGenetics#FutureofHealthCare#AIAgent#ClinicalDrugDevelopment#Innovation#Leadership#AILeadership
